MedTrace Logo

The Effect of Cannabis in Pancreatic Cancer

NCT03245658 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2023-12-18

No results posted yet for this study

Summary

Cannabinoids are known to increase appetite, but THC components have psychogenic properties too. CBD is the main component in the plant, and have only minimal psychogenic effects. The aim was to test the appetite stimulating effects of CBD in patients with pancreatic cancer in palliative treatment.

Conditions

  • Neoplasms Pancreatic
  • Cachexia; Cancer
  • Cannabis
  • Appetite Loss
  • Palliative Medicine
  • Morbidity
  • Mortality

Interventions

DRUG

THC and CBD Mixture

Individually titrated doses on daily basis

Sponsors & Collaborators

  • Jens Rikardt Andersen

    lead OTHER

Principal Investigators

  • Jens Rikardt Andersen, MD, MPA · University of Copenhagen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-06
Primary Completion
2018-05-06
Completion
2018-10-06

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03245658 on ClinicalTrials.gov